Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317892007> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W4317892007 endingPage "57" @default.
- W4317892007 startingPage "57" @default.
- W4317892007 abstract "57 Background: Metastatic colorectal cancer (mCRC) with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) show frequent and durable responses to programmed cell death -1 (PD-1) blockade. While the majority of these tumors are sporadics and observed in elderly patients, first-line data are limited to the KEYNOTE-177 study. Here, we report a consecutive series of elderly patients with dMMR mCRC treated with pembrolizumab in routine clinical practice that includes analysis of clinical outcome based on metastatic site. Methods: Patients with dMMR mCRC received first-line pembrolizumab (200 mg every 3 weeks) (N = 41) at Mayo Clinic and Mayo Clinic Health System (2015-2022). Clinicopathological features including metastatic site and molecular data ( BRAF V600E , KRAS) were analyzed in relationship to tumor response rate (RECIST version 1.1). Furthermore, these variables were also analyzed in relationship to patient progression-free survival (PFS) using Kaplan-Meier methodology and multivariable stepwise Cox regression. Results: Among patients with dMMR mCRC, 29/41 (70.7%) were female, 30 (78.9%) harbored BRAF V600E , and 32 (80%) were sporadic. Median age at start of treatment was 80.6 years (IQR of 75.9, 85.9) and median number of treatment cycles was 9 (IQR: 4, 20). At a median follow-up of 23 months (range, 3.0 to 88.5), patient median PFS was 21.3 months (95% CI: 6.4, 38.5). An overall response was observed in 48.8% (20 of 41) of patients including 13 (31.7%) complete (CR) and 7 (17.1%) partial responses (PR). The median duration of response was 42.2 months (95%CI: 8.6, NR). Patients with metastases that included liver had significantly poorer PFS compared to those with non-liver metastases (HR adj 3.40 (95%CI: 1.27-9.13); P adj = 0. 01). In this regard, responses (CR, PR) to pembrolizumab were observed in 3 (21.4%) patients with liver metastasis compared to 17 (62.9%) of those with non-liver metastases. Treatment-related grade 3 or 4 adverse events were observed in 9 (22.0%) patients of whom two discontinued therapy, and there was one treatment-related death. Conclusions: First-line therapy with pembrolizumab for dMMR mCRC significantly prolonged survival in an elderly patient population with manageable toxicity in routine clinical practice. Moreover, the survival benefit of pembrolizumab was significantly attenuated in patients with liver vs non-liver metastases." @default.
- W4317892007 created "2023-01-25" @default.
- W4317892007 creator A5006194799 @default.
- W4317892007 creator A5018405630 @default.
- W4317892007 creator A5019091131 @default.
- W4317892007 creator A5033844346 @default.
- W4317892007 creator A5049054454 @default.
- W4317892007 creator A5049291606 @default.
- W4317892007 creator A5052578524 @default.
- W4317892007 creator A5069073626 @default.
- W4317892007 creator A5088071269 @default.
- W4317892007 creator A5090608376 @default.
- W4317892007 date "2023-02-01" @default.
- W4317892007 modified "2023-09-27" @default.
- W4317892007 title "Efficacy of pembrolizumab as first-line therapy in patients with mismatch repair–deficient metastatic colorectal cancer in relation to the metastatic site." @default.
- W4317892007 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.57" @default.
- W4317892007 hasPublicationYear "2023" @default.
- W4317892007 type Work @default.
- W4317892007 citedByCount "1" @default.
- W4317892007 countsByYear W43178920072023 @default.
- W4317892007 crossrefType "journal-article" @default.
- W4317892007 hasAuthorship W4317892007A5006194799 @default.
- W4317892007 hasAuthorship W4317892007A5018405630 @default.
- W4317892007 hasAuthorship W4317892007A5019091131 @default.
- W4317892007 hasAuthorship W4317892007A5033844346 @default.
- W4317892007 hasAuthorship W4317892007A5049054454 @default.
- W4317892007 hasAuthorship W4317892007A5049291606 @default.
- W4317892007 hasAuthorship W4317892007A5052578524 @default.
- W4317892007 hasAuthorship W4317892007A5069073626 @default.
- W4317892007 hasAuthorship W4317892007A5088071269 @default.
- W4317892007 hasAuthorship W4317892007A5090608376 @default.
- W4317892007 hasConcept C104317684 @default.
- W4317892007 hasConcept C121608353 @default.
- W4317892007 hasConcept C126322002 @default.
- W4317892007 hasConcept C143998085 @default.
- W4317892007 hasConcept C180754005 @default.
- W4317892007 hasConcept C185592680 @default.
- W4317892007 hasConcept C2776694085 @default.
- W4317892007 hasConcept C2777701055 @default.
- W4317892007 hasConcept C2779767149 @default.
- W4317892007 hasConcept C2779984678 @default.
- W4317892007 hasConcept C2780057760 @default.
- W4317892007 hasConcept C2780739268 @default.
- W4317892007 hasConcept C2781187634 @default.
- W4317892007 hasConcept C31760486 @default.
- W4317892007 hasConcept C50382708 @default.
- W4317892007 hasConcept C526805850 @default.
- W4317892007 hasConcept C535046627 @default.
- W4317892007 hasConcept C55493867 @default.
- W4317892007 hasConcept C61320498 @default.
- W4317892007 hasConcept C71924100 @default.
- W4317892007 hasConceptScore W4317892007C104317684 @default.
- W4317892007 hasConceptScore W4317892007C121608353 @default.
- W4317892007 hasConceptScore W4317892007C126322002 @default.
- W4317892007 hasConceptScore W4317892007C143998085 @default.
- W4317892007 hasConceptScore W4317892007C180754005 @default.
- W4317892007 hasConceptScore W4317892007C185592680 @default.
- W4317892007 hasConceptScore W4317892007C2776694085 @default.
- W4317892007 hasConceptScore W4317892007C2777701055 @default.
- W4317892007 hasConceptScore W4317892007C2779767149 @default.
- W4317892007 hasConceptScore W4317892007C2779984678 @default.
- W4317892007 hasConceptScore W4317892007C2780057760 @default.
- W4317892007 hasConceptScore W4317892007C2780739268 @default.
- W4317892007 hasConceptScore W4317892007C2781187634 @default.
- W4317892007 hasConceptScore W4317892007C31760486 @default.
- W4317892007 hasConceptScore W4317892007C50382708 @default.
- W4317892007 hasConceptScore W4317892007C526805850 @default.
- W4317892007 hasConceptScore W4317892007C535046627 @default.
- W4317892007 hasConceptScore W4317892007C55493867 @default.
- W4317892007 hasConceptScore W4317892007C61320498 @default.
- W4317892007 hasConceptScore W4317892007C71924100 @default.
- W4317892007 hasIssue "4_suppl" @default.
- W4317892007 hasLocation W43178920071 @default.
- W4317892007 hasOpenAccess W4317892007 @default.
- W4317892007 hasPrimaryLocation W43178920071 @default.
- W4317892007 hasRelatedWork W1899127110 @default.
- W4317892007 hasRelatedWork W2405055573 @default.
- W4317892007 hasRelatedWork W2474280112 @default.
- W4317892007 hasRelatedWork W2754584868 @default.
- W4317892007 hasRelatedWork W2953576767 @default.
- W4317892007 hasRelatedWork W3040911471 @default.
- W4317892007 hasRelatedWork W3181536331 @default.
- W4317892007 hasRelatedWork W4286294620 @default.
- W4317892007 hasRelatedWork W4286296868 @default.
- W4317892007 hasRelatedWork W4317892007 @default.
- W4317892007 hasVolume "41" @default.
- W4317892007 isParatext "false" @default.
- W4317892007 isRetracted "false" @default.
- W4317892007 workType "article" @default.